5%咪喹莫特乳膏用于治疗光化性角化病。

Imiquimod 5% cream for the treatment of actinic keratoses.

作者信息

Somani N, Rivers J K

机构信息

Division of Dermatology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.

出版信息

Skin Therapy Lett. 2005 Mar;10(2):1-6.

PMID:15986078

Abstract

Actinic keratoses (AKs) are premalignant inflammatory skin lesions with the potential to transform into squamous cell carcinoma (SCC). There are several treatment options available for patients presenting with multiple AKs. Imiquimod is believed to stimulate and enhance host immune responses locally against skin tumors and viral infections. Five clinical studies to date have demonstrated its safety and efficacy in the treatment of actinic keratoses. Long-term follow-up studies examining recurrence rates are limited.

摘要

光化性角化病（AKs）是具有恶变潜能的炎性皮肤病变，有可能转变为鳞状细胞癌（SCC）。对于患有多发性AKs的患者，有几种治疗选择。咪喹莫特被认为可在局部刺激并增强宿主针对皮肤肿瘤和病毒感染的免疫反应。迄今为止，五项临床研究已证明其在治疗光化性角化病方面的安全性和有效性。关于复发率的长期随访研究有限。